Tarek Abbas

[NDT @NDTsocial]

🤩Check out the new August issue of NDT:

📖https://t.co/xHgnX54zAt

🧐Editor's choice:

KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP)

🔓https://t.co/iGxFpK2MOF

[Gunnar Henrik Heine @gunnar_heine]

Mandatory weekend reading for nephrologists:

Disease modification in lupus nephritis

https://t.co/zxJCXU9yqw

By an SLE all-star ensemble:
@AKronbichler @Lupusreference @smirioglu @LuvacsL @AnnetteBruchfe1 @StefanieSteige6 @sarah_m_moran @OhioStateNeph @KateIsabelle24

[Sayna Norouzi, MD, FASN @SaynaNorouzi]

#IgA nephropathy is moving fast right now. In this paper, we round up the latest #updates shaping the field; and there’s a lot to track.

This is a pivotal moment for #IgAN.

Staying current isn’t optional 💙 it’s how we turn research into real progress for patients: #more options, #fewer side effects, #longer remissions, and more #hope.

✨The field is moving. Let’s move with it. ✨

#IgAN #RareKidneyDisease #Neohrology #KidneyDisease

https://t.co/OA9DbwNRKR

[Jonathan Chávez @JonathanNefro]

La susceptibilidad para desarrollar enfermedad renal crónica se determina desde el periodo gestacional, cuando nuestras madres se exponen a tóxicos ambientales que condicionarán la nefrogénesis y la función renal

@LeslieZiga7 @DrArreolaG
Journal of Neph 2026
https://t.co/ppyEjVzaD0

[Nature Reviews Nephrology @NatRevNeph]

Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm https://t.co/pM4MAsRlMW

[Jonathan Chávez @JonathanNefro]

En incidentes en hemodiálisis, el 22% desarrolló síndrome de desequilibrio postdialítico realizando un protocolo de dosis incremental por sesión.

Sorprende que ni el síndrome urémico, ni la urea fueron factores asociados a esta complicación

CKJ 2026
https://t.co/xqjP3u1yP6

[AJKD @AJKDonline]

Obesity in CKD: Core Curriculum 2026

https://t.co/zH9CjtaBwS (FREE)

@kramer_holly

[Nature Reviews Nephrology @NatRevNeph]

Gene–disease relationships for glomerular phenotypes: expert recommendations from ClinGen https://t.co/1mKtdYLrX7

[AJKD @AJKDonline]

Purpura and Anasarca in a Kidney-Transplanted Recipient: A Quiz

https://t.co/1dvYc92jAN (FREE)

[Gopambuj Singh Rathod @IamGopambuj]

🩺 Podocyte-protecting drugs are changing modern nephrology practice.

Podocyte injury is a key driver of proteinuria and CKD progression. Important podocyte-protective therapies include:

✅ RAAS blockers (ACEi/ARBs)
✅ SGLT2 inhibitors
✅ Finerenone & other MRAs
✅ Calcineurin inhibitors
✅ Endothelin pathway inhibitors
✅ Rituximab in selected glomerular diseases

🎯 Goals:
• Reduce proteinuria
• Preserve glomerular filtration barrier
• Slow CKD progression
• Improve long-term renal outcomes

The strongest evidence today supports:
🛡️ RAAS blockade + SGLT2 inhibitor ± Finerenone
#GSR #BuddingNephros
#Nephrology #Proteinuria #KidneyDisease #GlomerularDisease #MedTwitter

[NDT @NDTsocial]

🤩The 2025 publications from the ERA bodies all in one place:
https://t.co/H4QF5KtrRk

🧐Selected for you:

KDIGO 2025 ADPKD guideline: a commentary on diagnosis and management of hepatopancreatic manifestations by the ERA Working Group Genes & Kidney

🆓https://t.co/KfmGoKQwBv

[Nature Reviews Nephrology @NatRevNeph]

Anti-neutrophil cytoplasmic antibody-associated vasculitis: biological insights and biomarker-guided disease management https://t.co/qmGOtMstYA

[AJKD @AJKDonline]

Current and Future Therapeutics for Focal Segmental Glomerular Sclerosis in the Era of Precision Medicine: A Review

https://t.co/RkHblc7Bg6 (OPEN ACCESS)

[NDT @NDTsocial]

Comparative Analysis of Lupus Nephritis Guidelines:

ACR 2025, EULAR 2025, and KDIGO 2024

🆓https://t.co/bUkps0GzvD

@goKDIGO @ERAkidney

[Dr. Jair Vargas @DrDeLaUCI]

LESIÓN RENAL AGUDA EN CIRROSIS ‼️

📌LRA en cirrosis ( Criterios KDIGO) :  

a) aumento de la creatinina sérica ≥0,3 mg/dl en 48 h o ≥50% del valor basal que se sabe o se presume que ocurrió en los 7 días anteriores y/o producción de orina ≤0,5 ml/kg durante ≥6 h

[Intissar HADDIYA @HaddiyaIntissar]

#FSGS: not 1 disease, but a pathway-driven syndrome
🔵 Immune/inflammatory
🟢 Circulating factors/permeability
🟠 Podocyte injury
🔴 Genetic/molecular
👉 From empirical therapy to mechanism-based TRT
📊 Biomarkers & targeted strategies below @AfricanAFRAN @ISNkidneycare @goKDIGO

[Marcos Gamboa @mrcsgmb84]

¿Es momento de abandonar la "dieta renal" tradicional restrictiva? 🚨 Les comparto datos de una revisión exploratoria sobre Nutrición Personalizada en Hemodiálisis. Un cambio de paradigma vital para el manejo del paciente cardiorenometabólico.
https://t.co/4W3TKWc9yn
@sociedadSEEN @SENefrologia @SLANH_ @apenut_info @malaga1711 @PerlaZambrano @Vic_Tos19 @fernandamdo @anaiscamacho

[AJKD @AJKDonline]

Beyond Diffusion: Clinical Perspectives on Online Hemodiafiltration and Medium Cut-Off Dialyzers

https://t.co/Ujc47x8Al9 (OPEN ACCESS)

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular Diseases

https://t.co/IUArI0avYU

[Virginia Cabello @VirginiaCabel10]

Extrarenal Disease in ANCA-Associated Vasculitis: Challenges and Evolving Therapeutic Strategies on behalf of the Immunonephrology Working Group (IWG) of the ERA https://t.co/B1JLrfOA2Q